Deregulated expression and/or activity of Protein Tyrosine Kinases (PTKs) and their downstream signaling proteins are now widely recognized as oncogenesis-driving mechanisms that are amenable to targeted therapies. Studies by the PI and others have established the Cbl family of ubiquitin ligases (E3s) as physiological negative regulators of PTK signaling. Cbl proteins interact with PTKs and their effectors to promote their ubiquitination resulting in degradation-dependent or degradation-independent negative regulation of PTK signaling. Consistent with the importance of this mechanism in PTK regulation, mutations of Cbl that cluster in regions (linker region and RING finger) essential for E3 activity have now been identified in a subset of patients with myeloproliferative neoplasms and leukemia. Notably, most patients show acquired Uniparental Disomy with mutant Cbl allele replacing the wildtype allele. These findings lead us to our working hypotheses that Cbl is a tumor suppressor and that mutant Cbl proteins attain transforming properties due dominant-negative inhibition of endogenous Cbl proteins together with a gain-of-function trait that is selected for in cancer. Based on biochemical studies in previous funding cycles of this grant and work by others, we hypothesize the following molecular mechanisms for oncogenesis by Cbl mutants: The E3-deficient Cbl mutants produce dominant-negative inhibition of Cbl and related Cbl-b by competing for binding to activated target PTKs. Mutant Cbl proteins also serve as supra- molecular scaffolds to juxtapose the associated hyperactive PTKs with mutant Cbl-bound signaling intermediates to create a gain of function oncogenic cascade. This combination of dominant-negative and GOF mechanisms is hypothesized to allow the mutant Cbl proteins to establish a PTK-dependent oncogenic signaling cascade. In this renewal application, we will leverage our vast expertise and unique resources to test this model using molecular, biochemical, cellular and animal-based analyses. We will use engineer oncogenic Cbl mutant proteins that cannot interact with upstream PTKs through the TKB domain or with other signaling effectors through their C-terminal regions. In vitro and in vivo oncogenesis studies of these engineered proteins in hematopoietic stem/progenitor cells derived from wildtype, Cbl-null, Cbl-b-null and Cbl/Cbl-b-null backgrounds (which are available) will help test the role of key structural domains of mutant Cbl in establishing dominant-negative and gain-of-function mechanisms to drive oncogenesis. The engineered mutants and hematopoietic stem/progenitor cells expressing these, together with cells from an available Cbl RING Finger Knock-In mouse model, will be used to identify PTK and signaling protein partners that are required for mutant Cbl oncogenesis. Multi-pronged overexpression, knock-down/knockout, dominant-negative protein expression and chemical inhibition approaches will validate the role of identified Cbl partners in oncogenesis. Successful accomplishment of the proposed goals will help bring together the conceptual frameworks established during the previous cycles of this grant together with recent advances in the field to elucidate the mechanisms by which Cbl mutations contribute to human cancer and provide a conceptual and experimental framework for novel options towards targeted therapy of patients with Cbl mutations and related malignancies.

Public Health Relevance

Loss of genes that suppress the tendency of normal cells to become cancerous (tumor supressor genes) and mutation of genes that lead to the formation of oncogenes serve as drivers of human cancer. Our laboratory studies a group of proteins, the Cbl protein family, that control the levels and activity of receptors on normal cells that help our cells receive and process external signals, and they function as molecular brakes. Recent studies have identified loss of normal Cbl and accumulation of mutant Cbl protein in a subset of human leukemias, indicating that normal Cbl functions as a tumor suppressor and the mutant version as an oncogene. Based on our prior and ongoing molecular, cellular and animal studies, further studies are proposed to decipher the exact molecular mechanisms of cancer induced by mutations of Cbl proteins. The lessons learned here are hoped to open avenues for designing new drugs to treat human cancers in which Cbl mutants serve as drivers of cancer. The insights generated here could also help understand mechanisms of oncogenesis in other prevalent cancers in which protein tyrosine kinases (which are targeted by Cbl proteins) are deregulated.

Agency
National Institute of Health (NIH)
Type
Research Project (R01)
Project #
5R01CA087986-16
Application #
8682788
Study Section
Cancer Molecular Pathobiology Study Section (CAMP)
Program Officer
Hildesheim, Jeffrey
Project Start
Project End
Budget Start
Budget End
Support Year
16
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Nebraska Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Omaha
State
NE
Country
United States
Zip Code
68198
Shukla, Ashima; Rai, Karan; Shukla, Vipul et al. (2016) Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL. Blood 127:2310-21
Mir, Riyaz A; Bele, Aditya; Mirza, Sameer et al. (2016) A Novel Interaction of Ecdysoneless (ECD) Protein with R2TP Complex Component RUVBL1 Is Required for the Functional Role of ECD in Cell Cycle Progression. Mol Cell Biol 36:886-99
Bhattacharyya, Sohinee; Rainey, Mark A; Arya, Priyanka et al. (2016) Endocytic recycling protein EHD1 regulates primary cilia morphogenesis and SHH signaling during neural tube development. Sci Rep 6:20727
Cypher, Luke R; Bielecki, Timothy Alan; Huang, Lu et al. (2016) CSF-1 receptor signalling is governed by pre-requisite EHD1 mediated receptor display on the macrophage cell surface. Cell Signal 28:1325-35
Raja, Srikumar M; Desale, Swapnil S; Mohapatra, Bhopal et al. (2016) Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. Oncotarget 7:10522-35
Curran, Jerry; Musa, Hassan; Kline, Crystal F et al. (2015) Eps15 Homology Domain-containing Protein 3 Regulates Cardiac T-type Ca2+ Channel Targeting and Function in the Atria. J Biol Chem 290:12210-21
Desale, Swapnil S; Raja, Srikumar M; Kim, Jong Oh et al. (2015) Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models. J Control Release 208:59-66
Bhagirath, Divya; Zhao, Xiangshan; West, William W et al. (2015) Cell type of origin as well as genetic alterations contribute to breast cancer phenotypes. Oncotarget 6:9018-30
Arya, Priyanka; Rainey, Mark A; Bhattacharyya, Sohinee et al. (2015) The endocytic recycling regulatory protein EHD1 Is required for ocular lens development. Dev Biol 408:41-55
Mohibi, Shakur; Srivastava, Shashank; Wang-France, Jun et al. (2015) Alteration/Deficiency in Activation 3 (ADA3) Protein, a Cell Cycle Regulator, Associates with the Centromere through CENP-B and Regulates Chromosome Segregation. J Biol Chem 290:28299-310

Showing the most recent 10 out of 95 publications